Life Molecular Imaging

Executive Summary

Life Molecular Imaging (LMI), now a wholly owned subsidiary of Lantheus Holdings, is a German biotech pioneer in positron emission tomography (PET) radiopharmaceuticals for neurodegenerative and cardiovascular diseases. LMI's flagship product, Neuraceq (florbetaben F-18), is an FDA-approved diagnostic imaging agent for beta-amyloid plaques in Alzheimer's disease, enabling early detection and patient stratification. The company's pipeline includes novel tracers targeting tau pathology, neuroinflammation, and cardiac conditions, leveraging Lantheus's commercial infrastructure for global expansion. By integrating advanced imaging biomarkers into clinical practice, LMI aims to transform disease characterization, improve therapeutic monitoring, and accelerate drug development in neurology and cardiology. As a key asset within Lantheus, LMI benefits from enhanced R&D capabilities and a broader portfolio of radiopharmaceuticals. Recent strategic focus includes expanding Neuraceq's label to include longitudinal assessment and developing next-generation tracers for earlier disease detection. The company is also exploring partnerships for automated production platforms to increase tracer accessibility. With the global PET market growing due to rising Alzheimer's prevalence and the advent of disease-modifying therapies, LMI is well-positioned to capture significant value. The acquisition by Lantheus provides financial stability and commercial reach, supporting ongoing clinical trials and regulatory submissions in the EU and Asia.

Upcoming Catalysts (preview)

• Q2 2026FDA label expansion for Neuraceq to include longitudinal amyloid monitoring60% success
• Q4 2026Phase 3 results for tau-PET tracer in Alzheimer's disease50% success
• Q3 2026Partnership announcement for automated production and supply chain expansion70% success